Full-Time

Quality Control Associate 2

Analytical

Posted on 9/5/2025

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$50k - $80k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (4)
, , ,
Requirements
  • B.S. or Associates and Certificates plus 2 years’ experience
  • 2-5 years of experience in a GMP Laboratory setting
  • Knowledge of the theoretical and practical aspects of analytical methods utilized to characterize large molecule therapeutics including U/HPLC, CE, cIEF, ELISA, SDS-PAGE and all compendial testing
  • Experience with preparing analytical test reports, qualification/validation protocols, qualification/validation reports and SOPs
  • Familiarity with compendia (USP, Ph. EUR, and JP) and ICH guidelines
  • Strong written and oral communication skills, proficiency with Microsoft Office software
Responsibilities
  • Performance of QC raw material, in-process, drug substance and drug product testing for release and stability, as well as support of testing/review of data with/from contract testing laboratories (e.g. compendial methods, HPLC, ELISA, CE, fluorescence assays, particle sizing, bioburden, endotoxin, etc.)
  • Provides critical QC centric review of draft Analytical Test Methods (ATMs) and qualification/validation protocols received from the Analytical Method Development (AMD) group
  • Executes qualification/validation protocols and writes technically sound qualification/validation reports
  • Participate in method and equipment qualification and validation in the QC laboratory
  • Provide review of QC data and associated documentation
  • Support laboratory investigations to determine root cause for OOS, OOT, Atypical and invalid test results
  • Contribute to laboratory operations by performing regular instrument calibration and minor instrument maintenance
  • Support operational systems (e.g. equipment maintenance, reagent prep, forms control, etc.)
  • Train on all relevant procedures, as appropriate
  • Operate to the highest ethical and moral standards
  • Demonstrate flexibility with changing priorities
  • Apply a working knowledge of compendia testing (USP, Ph. EUR, JP, etc.) wet chemistry techniques and analytical analysis (U/HPLC, CE, cIEF, ELISA, SDS PAGE, etc.)
  • Contribute to Quality Control department goals and objectives
  • Comply with Abzena's policies and procedures
  • Communicate effectively with clients, supervisors, colleagues and staff
  • Participate effectively as a team player in all aspects of Abzena's business
  • Adhere to quality standards set by regulations and Abzena policies, procedures, and mission
  • Perform other related duties as assigned

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.

INACTIVE